University of Zurich
Swiss and neighbouring institutes pioneer AAV-based delivery of prime editors for in-vivo correction of inherited metabolic liver defects.
- Country
- Switzerland
Coverage
| CN | EU | US | |
|---|---|---|---|
| genome-engineering | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Prime editing | genome-engineering | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.